Proteomics Market Size, Share & Forecast 2026-2032
Proteomics market at $35.03B in 2026, reaching $72.93B by 2032 at 13.0% — and why the disclosed pure-play platform sector is 121x smaller than the headline.
$35.0B
$72.9B
13%
Global
Executive Summary
Proteomics is the market in this corpus where the publishers agree and are collectively measuring the wrong thing. Estimates for 2025 run from BCC Research's $31.0 billion to $41.97 billion — a spread of only 1.35x, and published CAGRs cluster between 12.0% and 16.55%. We publish BCC's series, the narrowest stated scope and the only one with an explicit exclusion list: $35.03 billion in 2026 to $72.93 billion by 2032 at 13.0%, interpolated from BCC's own base and rate and checked against BCC's own 2030 figure to within 0.14%. What the agreement conceals is visible the moment the totals meet audited revenue. One publisher puts proteomics instruments alone at $8.0 billion for 2025; Thermo Fisher Scientific's entire Analytical Instruments segment, spanning chromatography, mass spectrometry, microscopy and chemical analysis across every application, was $7.55 billion in FY2025. The same publisher's $41.2 billion total is 3.75x the combined revenue of that segment and the whole of Bruker, and 92.5% of Thermo Fisher's entire company. Meanwhile the whole disclosed revenue of the next-generation proteomics platform sector — Quanterix, SomaLogic, Standard BioTools and Seer — is $340.5 million, or 0.83% of the headline. Illumina's cash price for SomaLogic, $350 million, is roughly the whole of it. The published figures are a measure of how much protein work the world does, including buffers and gels. They are not an addressable market, and nobody writing them says so.
Key Highlights
Headline
$35.03 billion in 2026 to $72.93 billion in 2032 at 13.0%, interpolated from BCC Research's own published 2025 base and rate
Published 2025 estimates span only 1.35x ($31.0B-$41.97B) — agreement that reflects a shared method, not a measured market
One publisher's proteomics instruments line, $8.0 billion for 2025, exceeds Thermo Fisher's entire $7.55 billion Analytical Instruments segment across all applications
That publisher's $41.2 billion total is 3.75x Thermo Fisher Analytical Instruments plus the whole of Bruker, and 92.5% of Thermo Fisher's entire $44.56 billion company revenue
Disclosed FY2025 revenue of the pure-play platform sector is $340.5 million — 0.83% of the headline, a factor of 121
Illumina paid $350 million cash for SomaLogic, roughly equal to the entire disclosed revenue of that sector
One publisher's consumables category, 69.4% of its total, is defined to include buffers, chromatography columns and electrophoresis gels
Market Overview
Market Context
Proteomics has two meanings and one market size, which is the source of nearly every error made about it. In the first meaning, proteomics is what laboratories do to proteins: run them on gels, separate them on columns, quantify them with antibodies, identify them on mass spectrometers. On that reading a $31-41 billion global figure is defensible, because it is counting a very large base of recurring laboratory supplies and services — and one publisher says so explicitly, defining its consumables category to include buffers and electrophoresis gels. In the second meaning, proteomics is a class of new high-plex platforms intended to do for proteins what sequencing did for nucleic acids. That is what the sector's venture funding, its acquisitions and its press releases are about, and it is measurable: $340.5 million of disclosed FY2025 revenue across Quanterix, SomaLogic, Standard BioTools and Seer. The two readings differ by about 100x. The supplier structure reinforces the point: the companies that actually hold the revenue — Thermo Fisher, Bruker, Danaher, Agilent — report proteomics nowhere, because for them it is an application of instruments sold into many markets. The companies that are proteomics report revenue in the tens of millions.
Published proteomics market estimates agree unusually well — $31.0 billion to $41.97 billion for 2025, a spread of only 1.35x — and that agreement is misleading rather than reassuring. All of them are counting protein-related laboratory and service spend, and one publisher defines its consumables category to include buffers, chromatography columns and electrophoresis gels. We publish the narrowest stated scope, BCC Research's: $35.03 billion in 2026 rising to $72.93 billion by 2032 at 13.0%. The finding is the gap underneath it. The entire disclosed FY2025 revenue of the next-generation proteomics platform sector — Quanterix, SomaLogic, Standard BioTools and Seer combined — is $340.5 million, which is 0.83% of a $41.2 billion published headline. A reader who treats the headline as an addressable market for a proteomics platform is out by roughly 100x.
Market Stage
Growth
Adoption Level
Ubiquitous as a method, early as a platform market
Key Trends
Market Forecast & Data
Base Year (2026)
$35.0B
Forecast (2032)
$72.9B
CAGR (2026-2032)
13%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $35.03B |
| 2027 | $39.58B |
| 2028 | $44.73B |
| 2029 | $50.55B |
| 2030 | $57.12B |
| 2031 | $64.54B |
| 2032 | $72.93B |
Our 13.0% is the bottom of the published range, applied to the lowest dated full-scope base, and the resulting series reproduces BCC Research's own 2030 figure to within 0.14% — so it is faithful to its source. Whether it is a useful forecast depends entirely on which market the reader has in mind. For protein-related tools and consumables spend, 13.0% is a claim that a very broad laboratory-supply base compounds at roughly twice nominal GDP, in a period when the largest supplier's instrument segment grew 1% reported and was flat organically, and the second-largest declined 4% organically. That is a forecast about recovering research budgets and about consumables pull-through, and it is the same bet the single-cell and spatial forecasts make. For the platform sector, the published rate is close to meaningless: a 13% rate on a $340.5 million disclosed base gives $728 million by 2032, which is a different report. The two identifiable things that could break the pattern are both step changes rather than rates — population-scale plasma proteomics contracts attached to biobank cohorts, and regulatory uptake of proteomic readouts under FDA's April 2025 new approach methodologies roadmap, which encourages their inclusion in IND submissions without requiring it or qualifying any specific assay. Readers should hold the two numbers separately and never apply a published CAGR across the boundary.
Market Dynamics
- Plasma and tissue biomarker discovery in drug development, which is the application that justifies high-plex platform purchases rather than incremental mass-spectrometry capacity
- A very wide consumables base: antibodies, assay kits, protein chips, buffers, chromatography columns and electrophoresis gels are recurring purchases independent of platform cycles, and are what makes the published market large
- Multiomics bundling by sequencing companies, with Illumina acquiring SomaLogic and Thermo Fisher holding Olink — proteomic content sold alongside genomic content to the same customer
- FDA's April 2025 new approach methodologies roadmap, which encourages non-animal, human-relevant data including molecular safety readouts in IND submissions and gives proteomic assays a regulatory use case
- Falling cost per protein measured as high-plex affinity panels compete with mass spectrometry on depth-per-dollar rather than on absolute coverage
Market Segmentation
By Type
- Instruments and software
- Consumables and reagents
- Services
By End User
- Pharmaceutical and biopharmaceutical companies
- Academic and research institutions
- Clinical and reference laboratories
- Contract research organisations
By Application
- Mass spectrometry platforms
- Affinity and biochip platforms
- Protein separation and electrophoresis
- Bioinformatics and computational analysis
Competitive Landscape
Thermo Fisher Scientific Inc.
Waltham, Massachusetts, United States
FY2025 revenue $44.56 billion, up 4% and 2% organically. Analytical Instruments $7.55 billion, up 1% and flat organically. Life Sciences Solutions $10.37 billion, up 8% and 3% organically, which contains the Olink affinity-proteomics business acquired in 2024 without a separate revenue line.
Bruker Corporation
Billerica, Massachusetts, United States
FY2025 revenue $3.44 billion, up 2% reported and down 4% organically. BSI CALID, which contains mass spectrometry, was $1.21 billion, up 11% — the only growing segment. BSI NANO $1.08 billion, down 2%; BioSpin $878.8 million, down 3%.
Illumina, Inc.
San Diego, California, United States
FY2025 revenue $4.34 billion, flat year-over-year. Completed the SomaLogic acquisition on 30 January 2026 for $350 million cash plus up to $75 million in near-term milestones and royalties, acquiring an aptamer-based platform, a kitted-panel consumables stream, about 250 employees and a CLIA- and CAP-certified laboratory in Boulder, Colorado. Expects the business to be non-GAAP operating profitable in 2027.
Quanterix Corporation
Billerica, Massachusetts, United States
FY2025 total revenue $138.9 million, up about 1% from $137.4 million. Simoa single-molecule immunoassay platforms, heavily used in neurology biomarker work. The figure includes $21.9 million of Akoya spatial product revenue from the acquisition close date; legacy product revenue fell 11%, and collaboration and licence revenue fell 66% to $1.5 million.
Standard BioTools Inc.
South San Francisco, California, United States
FY2025 continuing-operations revenue $85.3 million, reported 24 February 2026; fourth-quarter revenue $23.8 million, down 4%, with consumables down 17% to $9.0 million and instruments up 10% to $8.5 million. Over $40 million of annualised cost savings fully operationalised, targeting positive adjusted EBITDA exiting 2026.
Seer, Inc.
Redwood City, California, United States
Proteograph nanoparticle-based unbiased proteomics, used upstream of mass spectrometry. FY2025 revenue $16.6 million, up 17%, comprising $11.2 million product and $4.9 million service, at a 51% gross margin, after installing 33 instruments during the year.
Nautilus Biotechnology, Inc.
Seattle, Washington, United States
Single-molecule protein-analysis platform in development, aiming at broad proteome coverage without mass spectrometry.
Recent Developments
Completed the acquisition of SomaLogic from Standard BioTools on 30 January 2026 for $350 million in cash plus up to $75 million in near-term performance milestones and royalties, acquiring an aptamer-based proteomics platform and a CLIA- and CAP-certified laboratory in Boulder, Colorado.
Reported FY2025 revenue of $44.56 billion on 29 January 2026, with the Analytical Instruments segment at $7.55 billion, up 1% and flat organically, and Life Sciences Solutions at $10.37 billion, up 8% — the segment that contains the Olink proteomics business without a separate revenue line.
Reported FY2025 continuing-operations revenue of $85.3 million on 24 February 2026, against preliminary combined-company revenue of about $185 million including SomaLogic, and disclosed roughly $550 million of cash and investments after the divestiture.
Reported FY2025 revenue of $16.6 million on 26 February 2026, up 17%, against operating expenses of $86.5 million, having installed 33 Proteograph instruments during the year to reach an installed base of 82.
Reported FY2025 revenue of $3.44 billion on 12 February 2026, with the BSI CALID segment containing mass spectrometry up 11% to $1.21 billion — the only growing segment in a company that declined 4% organically.
Regulatory Landscape
Research Methodology
Secondary research
- BCC Research, Proteomics: Technologies and Global Markets, report BIO034G, published May 2025 — $27.6B (2024), $31.0B (2025), $57.2B (2030), 13.0%
- Global Market Insights, proteomics market, report GMI5391, February 2026 — $41.2B (2025), $45.7B (2026), $126.3B (2035), 12.0%; instruments $8B in 2025
- Thermo Fisher Scientific Inc., Form 8-K Exhibit 99.1, fourth-quarter and full-year 2025 results, 29 January 2026 (SEC EDGAR, CIK 97745)
- Bruker Corporation, fourth-quarter and full-year 2025 financial results, 12 February 2026
- Quanterix Corporation, Form 10-K for FY2025 (SEC EDGAR, CIK 1503274)
- Standard BioTools Inc., Form 8-K Exhibit 99.1, Q4 and FY2025 financial results, 24 February 2026 (SEC EDGAR, CIK 1162194)
- Seer, Inc., fourth-quarter and full-year 2025 financial results, 26 February 2026
- Illumina, Inc., announcement of the SomaLogic acquisition, 23 June 2025; completion 30 January 2026
- IMARC Group, proteomics market — $36.3B (2023) to $126.2B (2032), 14.4%
- Precedence Research via BioSpace — $31.55B (2023) to $110.13B (2032), 14.9%
- Association for Molecular Pathology v. FDA, order vacating the laboratory-developed tests final rule, 31 March 2025
- U.S. FDA roadmap on phasing out animal testing requirements for monoclonal antibodies and other drugs, 10 April 2025
Validation: The headline is one publisher's own base advanced at its own rate, labelled as interpolation: BCC Research's $31.0 billion for 2025 becomes $35.03 billion for 2026 and $72.93 billion for 2032 at 13.0%. The internal check is that the modelled 2030 point, $57.12 billion, sits 0.14% from BCC's separately published $57.2 billion for 2030. BCC was chosen because it publishes the narrowest stated scope and is the only house in the set to publish an explicit exclusion list (protein structural analysis and protein-expression products are out of scope), which makes it the most checkable, and because it carries the lowest base among dated full-scope series. Three grounding calculations were run against audited and reported FY2025 revenue. First, one publisher's proteomics instruments line of $8.0 billion for 2025 is 1.06x Thermo Fisher Scientific's entire Analytical Instruments segment revenue of $7.55 billion, a business spanning chromatography, mass spectrometry, microscopy and chemical analysis across all applications. Second, that publisher's $41.2 billion total is 3.75x the combined $10.99 billion of Thermo Fisher's Analytical Instruments segment and the whole of Bruker, and 92.5% of Thermo Fisher's entire $44.56 billion company revenue. Third, the summed disclosed FY2025 revenue of the next-generation proteomics platform sector — Quanterix $138.9 million, SomaLogic approximately $99.7 million derived as the difference between Standard BioTools' preliminary combined-company revenue of about $185 million and its $85.3 million of continuing operations, Standard BioTools continuing $85.3 million, and Seer $16.6 million — is $340.5 million, or 0.83% of the $41.2 billion headline, a factor of 121. Illumina's $350 million cash price for SomaLogic is roughly equal to that whole sum. These are scope and plausibility tests, not market estimates: they establish that the published figures measure protein-related laboratory and service spend rather than a purchasable platform market, and they do not establish the correct figure for either reading. The SomaLogic line is our own subtraction between two of one company's disclosures; Olink, Nautilus, Bruker's proteomics line and all private vendors sit outside the $340.5 million sum, so it is a floor. Regional, country and segment shares are published as empty or as plain strings because the only source offering them presents no method, and no vendor market share is published because none is disclosed.
Strategic Takeaways
Decide which proteomics you mean before quoting a size. Protein-related tools and consumables spend is $31-42 billion; the disclosed next-generation platform sector is $340.5 million. The gap is about 100x and no published report flags it.
Test any proteomics headline against instrument-company revenue. A $41.2 billion market implies an instruments line larger than Thermo Fisher's entire Analytical Instruments segment, which covers far more than proteomics.
Read the consumables definition. When buffers, chromatography columns and electrophoresis gels are inside it, the total is measuring laboratory activity, not a platform opportunity.
Use the acquisition prices as the reality check. Illumina paid $350 million in cash for SomaLogic — roughly the whole pure-play sector's annual revenue, and under 1% of the published market.
Expect the sector to keep consolidating into sequencing and diagnostics companies, which also means the public disclosure this analysis depends on will keep shrinking.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Life SciencesVeterinary Diagnostics Market$9.5B · 9.57% CAGR
- Life SciencesLiquid Biopsy Market$8.0B · 13.91% CAGR
- Life SciencesPharmacogenomics Market$6.8B · 6.6% CAGR
- Life SciencesAntimicrobial Resistance Diagnostics Market$5.3B · 6.26% CAGR
- Life SciencesSingle-Cell Sequencing Market$2.2B · 12.2% CAGR
- Life SciencesOrganoid and Organ-on-Chip Market$623.8M · 24.6% CAGR